Stahl A, Lepore D, Fielder A, et al. - Through a randomized, open-label, superiority multicentre, three-arm, parallel-group trial was done in 87 neonatal and ophthalmic centers in 26 countries om 225 infants, researchers assessed the efficiency and safety of intravitreal ranibizumab in comparison with laser therapy in the treatment of retinopathy of prematurity (ROP). One infant had an unfavorable structural outcome after ranibizumab 0·2 mg, in comparison with five successive to ranibizumab 0·1 mg and seven following laser therapy. Death, serious and non-serious systemic adverse events and ocular adverse events were evenly categorized among the three groups. Thus, in the treatment of ROP, ranibizumab 0·2 mg might be better than laser therapy, with fewer unfavorable ocular outcomes vs laser therapy and with an agreeable 24-week safety profile.